How to improve issuing, transfusion and follow-up of blood components in Southern and Eastern Mediterranean countries? A benchmark assessment.

[1]  H. Slama,et al.  Transfusion safety in the Maghreb region. , 2021, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[2]  R. Abdelfattah,et al.  Hematopoietic Stem Cell Transplantation in Egypt: Challenges and Opportunities , 2020, Mediterranean journal of hematology and infectious diseases.

[3]  Mohammad A Y Alqudah,et al.  Quality and safety measures in transfusion practice: The experience of eight southern/eastern Mediterranean countries , 2020, Vox sanguinis.

[4]  Mohammad A Y Alqudah,et al.  How to manage transfusion systems in developing countries: The Experience of Eastern and Southern Mediterranean countries , 2020, Transfusion medicine.

[5]  P. Bolton-Maggs,et al.  Conference report: International Haemovigilance Seminar and the SHOT Annual Symposium, 10–12 July 2018 , 2019, Transfusion medicine.

[6]  N. Kröger,et al.  Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends , 2018, Bone Marrow Transplantation.

[7]  O. Garraud,et al.  Can a decentralized blood supply system reach 100% voluntary nonremunerated donation? , 2018, The International journal of health planning and management.

[8]  C. Glisch,et al.  Evaluation of a two-sample process for prevention of ABO mistransfusions in a high volume academic hospital , 2018, BMJ open quality.

[9]  O. Garraud,et al.  How Can Eastern/Southern Mediterranean Countries Resolve Quality and Safety Issues in Transfusion Medicine? , 2018, Front. Med..

[10]  R. Chaudhary,et al.  Assessment of bedside transfusion practices at a tertiary care center: A step closer to controlling the chaos , 2018, Asian journal of transfusion science.

[11]  A. Bazarbachi,et al.  Trends in hematopoietic stem cell transplant activity in Lebanon. , 2017, Hematology/oncology and stem cell therapy.

[12]  M. Bekadja,et al.  Hematopoietic stem cell transplantation in Algeria. , 2017, Hematology/oncology and stem cell therapy.

[13]  T. Frietsch,et al.  Administration Safety of Blood Products - Lessons Learned from a National Registry for Transfusion and Hemotherapy Practice , 2017, Transfusion Medicine and Hemotherapy.

[14]  M. Angastiniotis,et al.  Mediterranean Journal of Hematology and Infectious Diseases Β-thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint , 2022 .

[15]  T. Ben Othman,et al.  Direct cost analysis of the second year post-allogeneic hematopoietic stem cell transplantation in the Bone Marrow Transplant Centre of Tunisia , 2017, Journal of market access & health policy.

[16]  Sunil V. Rao,et al.  Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage. , 2016, JAMA.

[17]  G. Folléa,et al.  Rethinking blood components and patients: Patient blood management. Possible ways for development in France. , 2016, Presse medicale.

[18]  N. Howard,et al.  Exploring the Effectiveness of Mandatory Premarital Screening and Genetic Counselling Programmes for β-Thalassaemia in the Middle East: A Scoping Review , 2015, Public Health Genomics.

[19]  S. Saidman,et al.  Anti‐HLA antibody testing in hematology patients , 2015, American journal of hematology.

[20]  A. Asamoah,et al.  Two samples for blood transfusion: single centre experience , 2014, Transfusion medicine.

[21]  Hannah Cohen,et al.  Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety , 2013, British journal of haematology.

[22]  I. Gross,et al.  Patient blood management and outcome, too early or not? , 2013, Best practice & research. Clinical anaesthesiology.

[23]  J. Freedman,et al.  Review article: Risks of anemia and related management strategies: can perioperative blood management improve patient safety? , 2013, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

[24]  S. Alavian,et al.  Lack of Knowledge About Hepatitis C Infection Rates Among Patients With Inherited Coagulation Disorders in Countries Under the Eastern Mediterranean Region Office of WHO (EMRO): A Meta-Analysis , 2012, Hepatitis monthly.

[25]  D. Spahn,et al.  Strategies to reduce the use of blood products: a European perspective , 2012, Current opinion in anaesthesiology.

[26]  M. El-Hazmi,et al.  Sickle cell disease in Middle East Arab countries , 2011, The Indian journal of medical research.

[27]  M. Aljurf,et al.  Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2008-2009: report on behalf of the Eastern Mediterranean Bone Marrow Transplantation (EMBMT) Group. , 2011, Hematology/oncology and stem cell therapy.

[28]  A. Szallasi,et al.  ‘Wrong blood in tube’: solutions for a persistent problem , 2011, Vox sanguinis.

[29]  M. El Sayed Zaki,et al.  Descriptive Epidemiology of Hemophilia and Other Coagulation Disorders in Mansoura, Egypt: Retrospective Analysis. , 2010, Mediterranean journal of hematology and infectious diseases.

[30]  A. Greinacher,et al.  Coombs’ crossmatch after negative antibody screening – a retrospective observational study comparing the tube test and the microcolumn technology , 2010, Vox sanguinis.

[31]  M. Koh,et al.  Transfusion errors and management , 2009 .

[32]  H. Abolghasemi,et al.  Plasma fractionation, a useful means to improve national transfusion system and blood safety: Iran experience , 2009, Haemophilia.

[33]  G. Aprili.  Safety in transfusion medicine. , 2008, Blood transfusion = Trasfusione del sangue.

[34]  Matthew Darlison,et al.  Global epidemiology of haemoglobin disorders and derived service indicators. , 2008, Bulletin of the World Health Organization.

[35]  G. Lévy.  [The pretransfusion bedside agglutination test is not a "Gold Standard"]. , 2008, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[36]  J. Gornbein,et al.  Nearly two decades using the check-type to prevent ABO incompatible transfusions: one institution's experience. , 2006, American journal of clinical pathology.

[37]  H. Cohen,et al.  Reducing adverse events in blood transfusion , 2005, British journal of haematology.

[38]  J. Chiaroni,et al.  Analysis of ABO discrepancies occurring in 35 French hospitals , 2004, Transfusion.

[39]  M F Murphy,et al.  Current performance of patient sample collection in the UK , 2004, Transfusion medicine.

[40]  P. Wijermans,et al.  The importance of antibodies against low‐incidence RBC antigens in complete and abbreviated cross‐matching , 2003, Transfusion.

[41]  M. Murphy,et al.  An international study of the performance of sample collection from patients , 2003, Vox sanguinis.

[42]  G. Garratty.  How concerned should we be about missing antibodies to low incidence antigens? , 2003, Transfusion.

[43]  Pascal Morel,et al.  Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998 , 2002, Transfusion.

[44]  C. Milkins,et al.  The computer crossmatch: a safe alternative to the serological crossmatch , 2000, Transfusion medicine.

[45]  P. Ingrand,et al.  Errors in Interpreting the Pretransfusion Bedside Compatibility Test , 2000 .

[46]  D. Mcclelland,et al.  Treating a sick process , 2008, Transfusion.

[47]  P. Ingrand,et al.  Reliability of the pretransfusion bedside compatibility test: association with transfusion practice and training , 2008, Transfusion.

[48]  W. Judd.  Requirements for the Electronic Crossmatch , 1998, Vox sanguinis.

[49]  C. Högman,et al.  Computerized Delivery Control – A Useful and Safe Complement to the Type and Screen Compatibility Testing , 1997, Vox Sanguinis.

[50]  WHO Regional Office for the Eastern Mediterranean , 1995 .

[51]  J. Linden,et al.  A report of 104 transfusion errors in New York State , 1992, Transfusion.

[52]  J. Kelton,et al.  A prospective study to determine the safety of omitting the antiglobulin crossmatch from pretransfusion testing , 1992, British journal of haematology.

[53]  B. Lichtiger,et al.  Identification of previous erythrocyte alloimmunization and the type and screen at a large cancer center. A 4‐year retrospective review , 1992, Cancer.

[54]  R. Strauss,et al.  Safety and cost-containment data that advocate abbreviated pretransfusion testing. , 1990, American journal of clinical pathology.

[55]  K. Sazama,et al.  Reports of 355 transfusion‐associated deaths: 1976 through 1985 , 1990, Transfusion.

[56]  I. Shulman.  The risk of an overt hemolytic transfusion reaction following the use of an immediate spin crossmatch. , 1990, Archives of pathology & laboratory medicine.

[57]  J B Henry,et al.  The type and screen: a safe alternative and supplement in selected surgical procedures , 1977, Transfusion.